GRACELL BIOTECHNOLOGIES-ADR (GRCL) Stock Analyst Ratings
USA - NASDAQ:GRCL - US38406L1035 - ADR
10.25 USD
+0.01 (+0.05%)
10.25 USD
0 (0%)
ChartMill assigns a Buy % Consensus number of 79% to GRCL. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 10.76. This target is 4.99% above the current price.
GRCL was analyzed by 15 analysts. The buy percentage consensus is at 79. So analysts seem to be have mildly positive about GRCL.
In the previous month the buy percentage consensus was at a similar level.
GRCL was analyzed by 15 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2024-02-22 | Stifel | Downgrade | Buy -> Hold |
| 2023-12-27 | Wells Fargo | Downgrade | Overweight -> Equal-Weight |
| 2023-12-27 | Piper Sandler | Downgrade | Overweight -> Neutral |
| 2023-12-26 | BTIG | Downgrade | Buy -> Neutral |
| 2023-12-26 | HC Wainwright & Co. | Downgrade | Buy -> Neutral |
| 2023-11-27 | Evercore ISI Group | Initiate | Outperform |
| 2023-10-19 | Stifel | Initiate | Buy |
| 2023-09-05 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2023-08-30 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2023-08-29 | Citigroup | Maintains | Buy -> Buy |
| 2023-08-14 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2023-06-13 | BTIG | Maintains | Buy -> Buy |
| 2023-05-26 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-02-16 | HC Wainwright & Co. | Reiterate | Buy |
| 2023-02-06 | HC Wainwright & Co. | Reiterate | Buy |
| 2022-12-08 | HC Wainwright & Co. | Initiate | Buy |
| 2022-09-22 | Citigroup | Initiate | Buy |
| 2022-06-01 | Cantor Fitzgerald | Initiate | Overweight |
GRACELL BIOTECHNOLOGIES-ADR / GRCL FAQ
What is the average price target for GRACELL BIOTECHNOLOGIES-ADR (GRCL) stock?
15 analysts have analysed GRCL and the average price target is 10.76 USD. This implies a price increase of 4.99% is expected in the next year compared to the current price of 10.25.
How do analysts rate GRACELL BIOTECHNOLOGIES-ADR (GRCL)?
The consensus rating for GRACELL BIOTECHNOLOGIES-ADR (GRCL) is 78.6667 / 100 . This indicates that analysts generally have a positive outlook on the stock.
How many analysts have analysed GRACELL BIOTECHNOLOGIES-ADR (GRCL)?
The number of analysts covering GRACELL BIOTECHNOLOGIES-ADR (GRCL) is 15.